ABSTRACT
Stroke, one of the leading causes of death around the globe, is expected to rise considerably by 2050. The expanding nanotechnology science offers a promising future for medical research treating stroke. Nanomaterials are expanding their application in stroke management by structure and function as in perfluorocarbon, iron oxide nanoparticles, gold nanoparticles, dendrimers, quantum dots, nanospheres, and other organic and inorganic nanostructures. Nanotechnology integrated with stem-cell therapy is a different hit in stroke treatment. Nonetheless, some challenges must be resolved before globalizing the use of nanomaterials in stroke treatment and other neurological disorders.
A stroke is an emergency medical condition that affects the brain. Stroke is the third leading cause of death in the US and fifth in other developing countries. Taking blood-clotting medicines, helps relieve symptoms by preventing blood clots. However, they cannot treat the cause of the disease that is causing them. Therefore, using body fluids for identifying and treating strokes will give better results. In general, giving medicine to the brain is difficult, and it is a big challenge. Nanosized small molecules help to overcome this problem. This review aims to summarize how stroke is managed and how these molecules can help.
Subject(s)
Metal Nanoparticles , Nanoparticles , Nanostructures , Stroke , Humans , Gold , Drug Delivery Systems , Central Nervous System , Nanostructures/chemistry , Stroke/drug therapy , NanotechnologyABSTRACT
Osteogenesis is an important developmental event that results in bone formation. Bone forming cells or osteoblasts develop from mesenchymal stem cells (MSCs) through a highly controlled process regulated by several signaling pathways. The osteogenic lineage commitment of MSCs is controlled by cell-cell interactions, paracrine factors, mechanical signals, hormones, and cytokines present in their niche, which activate a plethora of signaling molecules belonging to bone morphogenetic proteins, Wnt, Hedgehog, and Notch signaling. These signaling pathways individually as well as in coordination with other signaling molecules, regulate the osteogenic lineage commitment of MSCs by activating several osteo-lineage specific transcription factors. Here, we discuss the key signaling pathways that regulate osteogenic differentiation of MSCs and the cross-talk between them during osteogenic differentiation. We also discuss how these signaling pathways can be modified for therapy for bone repair and regeneration.
